Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Grace Therapeutics, Inc
GRCE
Healthcare
Biotechnology
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel...
, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:GRCE)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Next
(52)
•••
Francine01
X
Comment by
Francine01
on Jan 11, 2021 11:03am
RE:RE:Hi Francine
Hi everyone and happy new year. Hopefully 2021 will be better than 2020 for Acasti. Obviously, since 40% of patients were not HTG at week 0, it was mathematically impossible to reach stastical
...more
(3)
•••
Zamboni99
X
Comment by
Zamboni99
on Jan 11, 2021 10:36am
RE:Hi Francine
So would I and so do I. And now I'm in the black again.
(2)
•••
Super63
X
Post by
Super63
on Jan 09, 2021 1:52pm
Hi Francine
Would love to hear your current thoughts please. I still have alot of shares and still care about this company. Thanx!
(3)
•••
seanj1
X
Post by
seanj1
on Jan 08, 2021 1:25pm
Partnership
Based on recent crazy market activities and massive price jumps and volume, I think Acasti is in the process of a partnership with a big pharma. Capre can be sold OTC or a new more competent partner
...more
(5)
•••
leblereau
X
Comment by
leblereau
on Dec 30, 2020 2:30pm
RE:RE:Avoid the Boxing Day rush
Acasti is making a nice move today, and its US counterpart is showing convincing volume.
(80)
•••
bingostar
X
Comment by
bingostar
on Dec 29, 2020 10:27am
RE:Avoid the Boxing Day rush
Do not trust ZACKS or FOOL , they are full of s , the stock moved because some people moved it , there is no rationale behind the hype , maybe people were inflenced by a disney movie were krill were
...more
(5)
•••
leblereau
X
Post by
leblereau
on Dec 25, 2020 8:27pm
Avoid the Boxing Day rush
Acasti (ACST) Moves to Buy: Rationale Behind the Upgrade - December 25, 2020 - Zacks.com Looks like this is gonna gap up on Monday in the US and new investors are going to be paying a heavy premium
...more
(4)
•••
19LDS84
X
Comment by
19LDS84
on Dec 24, 2020 4:33pm
RE:No Clue ?
Either they're lying or incompetent. Story of acastis life. Should be back to the gutters in no time. Happy holidays
(13)
•••
LowtoHigh
X
Comment by
LowtoHigh
on Dec 24, 2020 9:40am
RE:Gang trading
back to where it should be today...which is usual blah.
(80)
•••
bingostar
X
Post by
bingostar
on Dec 24, 2020 8:52am
Gang trading
My explanation is that a group of fortunate investors decided to massively invest in microcap at the same time creating a solid uptrend and drag along small investors that are FOMO. With the
...more
(10)
•••
socc15
X
Post by
socc15
on Dec 24, 2020 8:42am
No Clue ?
More than half a billion shares traded and management has no idea what is going on? Says everything you need to know about Jan and her gang of overpaid incompetents.My bet is they do know, but won t
...more
(77)
•••
GoodOutlook2015
X
Post by
GoodOutlook2015
on Dec 23, 2020 5:59pm
Insider info of possible buyout
from Big pharma????
(2118)
•••
lscfa
X
Comment by
lscfa
on Dec 23, 2020 3:44pm
RE:no news !
LAVAL, Qubec, Dec. 23, 2020 (GLOBE NEWSWIRE) -- At the request of IIROC, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) wishes to confirm that the Company’s management and
...more
(80)
•••
bingostar
X
Post by
bingostar
on Dec 23, 2020 3:18pm
failed phase 3
I do not believe that this stock double up when management has released 2 communiqu that their clinic trials have failed and they will pursue other activities , meaning they could close the shop but
...more
(24)
•••
cdogou812
X
Post by
cdogou812
on Dec 23, 2020 2:49pm
back at a $1 tomorrow ?
:))))))) wondering whats up ???
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Alphamin Announces Record Fy2024 & Q4 2024 Tin Production Fy2025 Production Guidance Exploration Success
Have you held units of a TD mutual fund, other than through a discount broker? Learn more.
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*
Eminent's First Drill Hole Hits Significant Gold-Arsenic in Getchell Trend Analogue and Second Hole Drilling Commences
U.S. DOD Logistics Agency Highlights V.GPH Project to Develop Eco-Friendly Graphite-Based Fire-Fighting Material